PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,812 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 2,812 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $75.99, for a total transaction of $213,683.88. Following the sale, the vice president owned 103,901 shares in the company, valued at approximately $7,895,436.99. This trade represents a 2.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Mark Elliott Boulding also recently made the following trade(s):

• On Tuesday, October 7th, Mark Elliott Boulding sold 3,375 shares of PTC Therapeutics stock. The shares were sold at an average price of $63.43, for a total value of $214,076.25.
• On Friday, October 3rd, Mark Elliott Boulding sold 22,655 shares of PTC Therapeutics stock. The stock was sold at an average price of $65.82, for a total transaction of $1,491,152.10.
• On Monday, October 6th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The stock was sold at an average price of $65.07, for a total value of $147,448.62.
• On Thursday, September 11th, Mark Elliott Boulding sold 22,664 shares of PTC Therapeutics stock. The shares were sold at an average price of $61.00, for a total value of $1,382,504.00.
• On Friday, September 12th, Mark Elliott Boulding sold 24,585 shares of PTC Therapeutics stock. The stock was sold at an average price of $61.34, for a total transaction of $1,508,043.90.

PTC Therapeutics Stock Down 1.4%

NASDAQ PTCT traded down $1.09 on Wednesday, reaching $75.60. 1,022,703 shares of the stock traded hands, compared to its average volume of 1,122,588. PTC Therapeutics, Inc. has a 12 month low of $35.95 and a 12 month high of $77.46. The company has a market cap of $6.07 billion, a price-to-earnings ratio of 10.85 and a beta of 0.60. The firm’s fifty day simple moving average is $66.02 and its 200 day simple moving average is $54.90.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. The firm had revenue of $211.01 million for the quarter, compared to analysts’ expectations of $177.42 million. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.PTC Therapeutics’s revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.39) EPS. PTC Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. UBS Group raised their target price on PTC Therapeutics from $71.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. Wells Fargo & Company boosted their target price on shares of PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. TD Cowen raised their price target on PTC Therapeutics from $50.00 to $63.00 and gave the stock a “hold” rating in a research report on Wednesday, November 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $118.00 price target on shares of PTC Therapeutics in a report on Wednesday, September 3rd. Finally, Bank of America cut their target price on PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, PTC Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $75.40.

Institutional Trading of PTC Therapeutics

Several hedge funds have recently modified their holdings of the stock. Smartleaf Asset Management LLC grew its position in PTC Therapeutics by 101.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 236 shares in the last quarter. Optiver Holding B.V. grew its holdings in shares of PTC Therapeutics by 96.5% during the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 249 shares during the last quarter. Comerica Bank boosted its holdings in shares of PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares during the period. Quantbot Technologies LP grew its holdings in shares of PTC Therapeutics by 545.5% during the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 551 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in shares of PTC Therapeutics by 84.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 320 shares in the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.